Fair Value Measurements - Financial Instruments at Fair Value (Details) - USD ($) $ in Millions			3 Months Ended		9 Months Ended
		Mar. 27, 2017	Oct. 01, 2016	Apr. 02, 2016	Sep. 30, 2017		Oct. 01, 2016	Jul. 01, 2017	Dec. 31, 2016		Oct. 02, 2016	Jul. 02, 2016	Apr. 03, 2016	Dec. 31, 2015
Assets:
Financial assets					$ 0.0				$ 2,350.0
Indefinite-lived intangible assets(2)			$ 674.4				$ 674.4				$ 674.2		$ 364.5
Liabilities:
Indefinite-lived intangibles carrying amount					103.4				114.5
Finite-lived intangible assets					4,621.5				4,417.2
Net proceeds from sale of business and other assets					46.7		58.5
Measured at fair value on a recurring basis: | Level 1
Assets:
Investment securities					6.1				38.2
Measured at fair value on a recurring basis: | Level 2
Assets:
Foreign currency forward contracts					13.1				3.8
Funds associated with Israeli severance liability					16.1				15.9
Total level 3 assets					29.2				19.7
Liabilities:
Foreign currency forward contracts					3.3				5.0
Measured at fair value on a recurring basis: | Level 3
Assets:
Financial assets					0.0				2,350.0
Total level 3 assets					143.2				2,350.0
Measured at fair value on a non-recurring basis: | Level 3
Assets:
Goodwill(1)					0.0				1,148.4	[1]
Indefinite-lived intangible assets(2)	[2]				13.3				0.3
Definite-lived intangible assets(3)					11.5	[3]		$ 11.5	758.0	[3]
Assets held for sale, net					95.1				18.2
Total level 3 assets					119.9				1,924.9
Liabilities:
Goodwill									2,200.0
Indefinite-lived intangibles carrying amount					26.0				0.7
Contingent consideration | Measured at fair value on a recurring basis: | Level 3
Liabilities:
Contingent Consideration			75.0		44.9		75.0	49.7	69.9			$ 44.9		$ 17.9
Accounts Receivable [Member] | Measured at fair value on a recurring basis: | Level 3
Assets:
Royalty Pharma contingent milestone payments					$ 143.2			$ 145.8	$ 0.0
Omega | Brands
Liabilities:
Impairment of intangible assets			$ 575.7	$ 273.4
Definite lived asset impairment							$ 290.9
Royalty Pharma
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sale price of divestiture - cash plus non-cash		$ 2,850.0
Liabilities:
Net proceeds from sale of business and other assets		2,200.0
Contingent Proceeds from Divestiture of Business, Milestone One, Maximum		250.0
Contingent Proceeds from Divestiture of Business, Milestone Two, Maximum		$ 400.0

[1] (1) As of December 31, 2016, goodwill with a carrying amount of $2.2 billion was written down to its implied fair value of $1.1 billion

[2] (2) As of September 30, 2017, indefinite-lived intangible assets with a carrying amount of $26.0 million were written down to a fair value of $13.3 million. As of December 31, 2016, indefinite-lived intangible assets with a carrying amount of $0.7 million were written down to a fair value of $0.3 million.

[3] (3) As of July 1, 2017, definite-lived intangible assets with a carrying amount of $31.1 million were written down to a fair value of $11.5 million. As of December 31, 2016, definite-lived intangible assets with a carrying amount of $2.3 billion were written down to a fair value of $758.0 million. Included in this balance are indefinite-lived intangible assets with a fair value of $364.5 million and $674.2 million that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.